2026年10月21日 / 美国东部时间上午11:35 / 哥伦比亚广播公司新闻
华盛顿讯——美国最高法院周三维持下级法院裁决,驳回特朗普政府此前试图叫停一项联邦监狱管理局新规的诉求,该新规将终止针对跨性别囚犯的部分医疗干预措施。
最高法院以无署名的单行命令形式,驳回了司法部提出的紧急上诉请求。司法部请求最高法院冻结地区法院的禁令,恢复这项新规。新规将停止为已被诊断或将被诊断为性别烦躁的囚犯提供手术、激素治疗以及社会住宿便利。
大法官塞缪尔·阿利托和克拉伦斯·托马斯表示,他们本会支持特朗普政府实施这项新规。
特朗普政府于上月向最高法院提起诉讼,请求介入这一争端,辩称这项针对跨性别囚犯的新规对于“维护监狱制度安全”至关重要。
但挑战该新规的联邦监狱中一名跨性别女性和两名跨性别男性的律师指出,联邦监狱管理局自1992年起就一直在为患有性别烦躁的囚犯提供激素治疗。他们表示,这项新规将导致该机构监管下的近1000名囚犯终止治疗。
最高法院审理的这起争端源于囚犯们去年提起的诉讼,他们代表被诊断为性别烦躁的在押人员起诉特朗普政府。诉讼发起于特朗普发布行政令之后,该行政令禁止使用联邦资金为联邦监狱管理局监管下的跨性别囚犯提供医疗手术或治疗。
作为对特朗普指令的回应,联邦监狱管理局于2月发布新规,称将不再提供用于治疗性别烦躁的手术或激素治疗。正在接受激素治疗的囚犯将被纳入逐步减量方案,最终完全停止此类干预措施。
根据新规,联邦监狱管理局也将不再为患有性别烦躁的囚犯提供任何社会住宿便利,例如胸部衬垫、束身衣、假发和化妆品。
在伴随该政策发布的一份备忘录中,联邦监狱管理局援引了特朗普的行政令,称其修改规则是为了“反映与最新科学信息更一致的性别烦躁治疗方案,符合BOP长期以来为囚犯量身提供医疗护理的政策,并考虑到惩教环境中复杂的安全和管理问题”。
今年6月,美国地区法官罗伊斯·兰伯思发布禁令,阻止特朗普政府实施2月的新规。法官要求联邦监狱管理局继续为患有性别烦躁的在押人员群体提供医疗干预措施和社会住宿便利。
“法庭并未介入针对跨性别群体的文化战争,”由罗纳德·里根总统任命的兰伯思在一份长达31页的裁决书中写道,“法庭只是认定,政府在发布限制为被诊断为性别烦躁的囚犯提供性别确认护理的新规时,违反了联邦法律。”
兰伯思于8月发布命令,继续叫停该政策。
随后,美国哥伦比亚特区巡回上诉法院的一个三人法官团拒绝解除地区法院的禁令。该上诉法院以2比1的投票结果裁定,联邦监狱管理局“未充分考虑其根据此前政策提供性别确认护理的自身经验”,且未能有力证明其在案件实质问题上有可能胜诉。
在向最高法院提起的紧急上诉中,副检察长D.约翰·绍尔辩称,地区法院的裁决“在广泛范围内阻止了政府所选定政策的实施”。
绍尔为这项终止跨性别囚犯医疗治疗的政策的合法性进行辩护,称联邦监狱管理局“在认定此类干预措施并非医疗必需,以及认定安全和监狱管理问题本身有理由改变政策时,适时考虑了其过往经验”。
但针对政府新规的反对者辩称,特朗普政府未提供任何证据表明联邦监狱管理局的医疗人员认为目前受限的医疗治疗是有效、无效还是有害的。
“BOP终止了其医疗人员数十年来一直推荐的治疗方案,取而代之的是心理治疗——其自身专家承认,这种治疗没有任何证据证明其对性别烦躁的治疗效果——以及精神科药物——BOP的医疗总监甚至并未声称这类药物可治疗性别烦躁,仅能治疗共病,”跨性别囚犯的律师写道。
他们还指出,该机构并未“指出一起与为治疗性别烦躁提供医疗干预相关的安全事件”。
“如果BOP的医生认为这种治疗对患者无益或有害,或者该机构认为该治疗损害了安全,那么BOP肯定会在行政记录中提及此事,”原告律师表示,“这一明显的疏漏,以及其决定的不合理性,清楚表明这些理由是为了支持特朗普总统在行政令中提出的要求而编造的。”
https://www.cbsnews.com/video/justice-alito-supreme-court-not-part-political-movement/
最高法院大法官阿利托:“我们不属于任何政治运动”
(时长01:05)
Supreme Court rejects Trump bid to restrict some medical treatments for transgender inmates
October 21, 2026 / 11:35 AM EDT / CBS News
Washington — The Supreme Court on Wednesday left intact a lower court decision that blocked the Trump administration from enforcing a new Bureau of Prisons policy that would end certain medical interventions for transgender inmates.
In an unsigned, one-line order, the high court rejected an emergency appeal from the Justice Department asking it to freeze the district court order and revive the new rules. The policy would cut off surgical and hormone therapy treatments, as well as social accommodations, for inmates who have been or will be diagnosed with gender dysphoria.
Justices Samuel Alito and Clarence Thomas said they would have allowed the Trump administration to enforce the change.
The Trump administration sought the Supreme Court’s intervention in the dispute last month and argued that the new policy for transgender inmates is needed to “maintain institutional security.”
But lawyers for a transgender woman and two transgender men in federal prisons who challenged the rules said the Bureau of Prisons has provided hormone treatment to people with gender dysphoria since 1992. They said that the new policy required the end of treatment for nearly 1,000 inmates in the bureau’s custody.
The dispute before the Supreme Court stems from a lawsuit the inmates filed against the Trump administration last year on behalf of incarcerated people diagnosed with gender dysphoria. The suit was filed after President Trump issued an executive order that barred the use of federal funds for medical procedures or treatments for transgender inmates who are in Bureau of Prisons custody.
In response to Mr. Trump’s directive, the Bureau of Prisons issued a new policy in February stating that it would not provide surgeries or hormone therapy to address gender dysphoria. Inmates who were receiving hormone treatments could be put on a tapering plan that would eventually lead to a discontinuation of the interventions.
Under the new rules, the Bureau of Prisons will also no longer provide any social accommodations, such as breast padding, binders, wigs and makeup, to inmates with gender dysphoria.
In a memo accompanying the policy, the Bureau of Prisons cited Mr. Trump’s executive order and said it changed its rules to “reflect treatment for gender dysphoria that is more aligned with the latest scientific information, that is consistent with BOP’s longstanding policy of providing medical care that is tailored to the unique needs of the inmate, and that accounts for the complex security and administration concerns in the correctional environment.”
In June, U.S. District Judge Royce Lamberth issued an order preventing the Trump administration from enforcing the February policy. The judge required the Bureau of Prisons to continue providing medical interventions and social accommodations to a class of inmates with gender dysphoria.
“The court does not wade into the culture war being waged against transgender individuals,” Lamberth, who was appointed by President Ronald Reagan, wrote in a 31-page decision. “The court simply concludes that the government violated [federal law] when it issued a new policy restricting the provision of gender-affirming care to inmates diagnosed with gender dysphoria.”
Lamberth issued an order in August that continued to block the policy.
A three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit then declined to lift the district court’s injunction. In a 2-1 decision, the appeals court said the Bureau of Prisons “did not adequately consider its own experience providing gender-affirming care under its prior policy” and failed to make a strong showing that it is likely to succeed on the merits of the case.
In its emergency appeal to the Supreme Court, Solicitor General D. John Sauer argued that the district court’s decision “prevents the application of the Executive’s chosen policy” on a broad basis.
Sauer defended the legality of the policy ending medical treatments for transgender inmates and said the Bureau of Prisons “seasonably considered its prior experience both in determining that such interventions are not medically necessary and in determining that security and prison-administration concerns independently justified a change in policy.”
But the challengers of the administration’s new rules argued the Trump administration failed to put forth any evidence indicating whether healthcare providers for the Bureau of Prisons found the now-restricted medical treatments to be effective, ineffective or harmful.
“BOP cut off treatment that its healthcare providers had recommended for decades and replaced it with psychotherapy — which its own expert acknowledges is backed by no evidence demonstrating its efficacy as a treatment for gender dysphoria — and psychotropic medications — which BOP’s Medical Director does not even claim treat gender dysphoria, only co-existing conditions,” lawyers for the transgender inmates wrote.
They also argued that the agency has not “pointed to a single security incident” relating to the provision of medical interventions to address gender dysphoria.
“Had BOP’s doctors found this treatment unhelpful or harmful to patients or had the agency found that the treatment compromised security, surely BOP would have mentioned it in the administrative record,” lawyers for the plaintiffs said. “That glaring omission, as well as the unreasonableness of its decision, make it clear that the rationales were contrived to support the demand President Trump made in the EO.”
https://www.cbsnews.com/video/justice-alito-supreme-court-not-part-political-movement/
Justice Alito on the Supreme Court: “We are not part of any political movement”
(01:05)
发表回复